Fisher Asset Management LLC Takes $780,000 Position in Intercept Pharmaceuticals, Inc. (ICPT)

Fisher Asset Management LLC bought a new position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,436 shares of the biopharmaceutical company’s stock, valued at approximately $780,000. Fisher Asset Management LLC owned approximately 0.05% of Intercept Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Sphera Funds Management LTD. increased its holdings in Intercept Pharmaceuticals by 100.0% in the second quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock worth $3,632,000 after purchasing an additional 15,000 shares in the last quarter. Oppenheimer & Co. Inc. increased its holdings in Intercept Pharmaceuticals by 9.0% in the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 178 shares in the last quarter. Vanguard Group Inc. increased its holdings in Intercept Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after purchasing an additional 57,149 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in Intercept Pharmaceuticals by 85.6% in the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after purchasing an additional 3,136 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Intercept Pharmaceuticals by 12.8% in the first quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock worth $16,301,000 after purchasing an additional 16,392 shares in the last quarter. Institutional investors and hedge funds own 82.81% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Fisher Asset Management LLC Takes $780,000 Position in Intercept Pharmaceuticals, Inc. (ICPT)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/10/31/fisher-asset-management-llc-takes-780000-position-in-intercept-pharmaceuticals-inc-icpt.html.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) opened at 63.29 on Tuesday. The stock’s market cap is $1.59 billion. Intercept Pharmaceuticals, Inc. has a 12 month low of $54.98 and a 12 month high of $135.59. The company’s 50 day moving average price is $71.79 and its 200 day moving average price is $104.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. During the same quarter last year, the company earned ($3.14) EPS. The firm’s revenue for the quarter was up 459.6% on a year-over-year basis. Equities analysts forecast that Intercept Pharmaceuticals, Inc. will post ($13.99) EPS for the current fiscal year.

ICPT has been the subject of a number of research analyst reports. Wedbush reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 target price on shares of Intercept Pharmaceuticals in a report on Sunday, July 30th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 target price for the company in a report on Tuesday, July 11th. Finally, Cowen and Company reiterated a “buy” rating and issued a $112.00 target price (down from $232.00) on shares of Intercept Pharmaceuticals in a report on Friday, September 22nd. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $153.76.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 253 shares of Intercept Pharmaceuticals stock in a transaction on Friday, August 25th. The stock was sold at an average price of $111.31, for a total value of $28,161.43. Following the completion of the sale, the insider now owns 23,324 shares of the company’s stock, valued at approximately $2,596,194.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO David Shapiro sold 1,250 shares of Intercept Pharmaceuticals stock in a transaction on Friday, September 1st. The stock was sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the sale, the chief marketing officer now directly owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,211 shares of company stock valued at $341,636. 4.50% of the stock is owned by corporate insiders.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit